Anne-Marie Koop

1 21 39. Wilkins BJ, Windt LJ De, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin- Mediated Cardiac Hypertrophic Growth. Mol Cell Biol 2002;22:7603–7613. 40. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93 :215– 228. 41. Dolinsky VW, Soltys CLM, Rogan KJ, Chan AYM, Nagendran J, Wang S, Dyck JRB. Resveratrol prevents pathological but not physiological cardiac hypertrophy. J Mol Med 2015; 93 :413–425. 42. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy. Circ Res 2004;94:110–118. 43. Taegtmeyer H, Sen S, Vela D. Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci 2010;1188:191–198. 44. Archer SL, Fang Y-H, Ryan JJ, Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 2013;3:144–152. 45. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951–1960. 46. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: Disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res S.L. Archer, Department of Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; 2014;115:176–188. 47. Redout EM, Wagner MJ, Zuidwijk MJ, Boer C, Musters RJP, Hardeveld C van, Paulus WJ, Simonides WS. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res W.S. Simonides, Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, Netherlands; 2007;75:770–781. 48. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol - Hear Circ Physiol 1998;275:1948–1956. 49. Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, Berger RMF. A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Int J Cardiol Elsevier Ireland Ltd; 2013;169:183–189. 50. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy A, Provencher S, Bonnet S, Michelakis ED. A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension. Circ Res 2015;116:56–69. 51. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, Schlippenbach J Von, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschöpe C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Hear Fail 2011;4:44–52. 52. Harvey PA, Leinwand LA. Cellular mechanisms of cardiomyopathy. J Cell Biol 2011;194: 355–365.